New HIV combo pill tested alongside TB treatment in small trial

NCT ID NCT07631897

Not yet recruiting Disease control Sponsor: Shanghai Public Health Clinical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will compare two different HIV medication combinations in 60 people who also have active tuberculosis. Participants will receive either a newer drug (Ainuovirine) or a standard one (Efavirenz), along with their TB meds. The goal is to see which regimen better suppresses the HIV virus and improves immune function over 48 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ainuovirine, Lamivudine, Tenofovir, and Efavirenz
What this could lead to: If successful, this could show that a newer HIV drug (Ainuovirine) works as well or better than the standard (Efavirenz) when taken alongside TB treatment, offering a safer or more effective option for co-infected patients.
What could go wrong: This is a small, early-stage (Phase 4) study with only 60 participants, so results may not apply to everyone. Drug interactions or side effects could still cause problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACTIVE TUBERCULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

active tuberculosis HIV infectious disease latent tuberculosis infection tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ART THERAPY HIV TB - TUBERCULOSIS

More trials for these conditions

Other studies related to the condition(s) this trial covers.